Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 21.10.2021 16:25
Latest

6.10 NOK

Change

0.00

Change (%)

0.00

Share information

IR contact

News

Reports

Governance

HBC 1
LATEST REPORT

Annual Report

Download our latest report, or view all quarterly and yearly reports in the archives.

Annual report 2020
All reports
16:9
NEXT UP

Financial calendar

Half-yearly Report
27.08.2021

Quarterly Report Q3
05.11.2021

Quarterly Report Q4
04.02.2022

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Stock exchange notices

View all notices

MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER IN HBC

01.10.2021

HBC ONBOARDS EX-NOVARTIS AND EX-PFIZER SENIOR REGULATORY AFFAIRS PROFESSIONAL, DR ZUBAIR HUSSAIN

22.09.2021

HBC HIRES EX DKSH SENIOR EXECUTIVE DR TANJA SCHAFFER, TO HEAD UP ITS GLOBAL INGREDIENTS BUSINESS AND AS CEO OF HBC SWITZERLAND GMBH

17.09.2021

MANDATORY NOTIFICATION OF TRADE

30.08.2021

SECOND QUARTER 2021 FINANCIAL REPORT

27.08.2021

Contact investor relations

James portrett
James Berger
Chief Commercial Officer
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford portrett
Dr. Crawford Currie
Head of Medical R&D
+44 7968 195497 cc@hofsethbiocare.no